NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Clinical Practice – Surveillance Programme

Recommendation for Guidance Executive

Clinical guideline
CG147: Lower limb peripheral arterial disease - diagnosis and management

Publication date
August 2012

Surveillance report for GE
November 2014 (2 year surveillance review)

Surveillance recommendation
Further to the Evidence Update on CG147: Lower limb peripheral arterial disease - diagnosis and management, where no impacts were identified, GE is asked to consider the proposal to not update the guideline at this time.

Key findings

<table>
<thead>
<tr>
<th>Potential impact on guidance</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence identified from Evidence Update</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Anti-discrimination and equalities considerations</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No update</th>
<th>CGUT update</th>
<th>Standard update</th>
<th>Transfer to static list</th>
<th>Change review cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Background information
Guideline issue date: August 2012
NCC: National Clinical Guideline Centre

Main findings of the current two year surveillance review
1. The Evidence Update on CG147: Lower limb peripheral arterial disease was used as the primary source of evidence for this surveillance decision (search dates: 9 January 2012 to 26 June 2014). A summary of the evidence is provided in the Evidence Update.

2. The Evidence Update indicates that there is currently insufficient new evidence to invalidate the existing guideline recommendations. Therefore the Surveillance Programme recommends no update at this time.

Ongoing research
3. Not considered at the 2-year review point.

Anti-discrimination and equalities considerations
4. None identified through the Evidence Update.
Implications for other NICE programmes
5. None identified through the Evidence Update.

Surveillance recommendation
6. GE is asked to consider the proposal to not update the guideline at this time. GE is asked to note that as a 2-year surveillance decision this ‘no to update’ proposal will not be consulted on.

Mark Baker – Centre Director
Sarah Willett – Associate Director
Khalid Ashfaq – Technical Analyst

Centre for Clinical Practice
November 2014